This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, PK, and PD profiles of a novel Fc-engineered IgG1 anti-CTLA-4 human monoclonal antibody (AGEN1181), and to assess the maximum tolerated dose (MTD) in subjects with advanced solid tumors. This study will also determine the RP2D of AGEN1181 monotherapy.
Inclusions/Exclusions: Recist 1.1 measurable disease. ECOG 0 or 1. Has not received anti-CTLA-4 antibody or drug. No standard therapy or standard therapy has failed. Stable brain metastasis allowed.